CSIMarket
 


Alx Oncology Holdings Inc  (ALXO)
Other Ticker:  
 

Cumulative Alx Oncology Holdings Inc's Long Term Debt to Equity for Trailing Twelve Months Period

ALXO's Long Term Debt to Equity for Trailing Twelve Months Period and Long Term Debt, Equity growth


Select the Comparisons : Select the Ratio:

ALXO Long Term Debt to Equity for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity Growth -41.19 % -32.76 % -30.04 % -27.43 % -25.5 %
Y / Y Long Term Debt Growth - - - - -
Long Term Debt to Equity for Trailing Twelve Months Period 0.04 0.03 0.02 0.01 -
Total Ranking # 293 # 257 # 190 # 174 #
Seq. Equity Growth -20.66 % -11.52 % -8.76 % -8.19 % -9.28 %
Seq. Long Term Debt Growth 0.66 % 0.66 % 0.65 % - -


Long Term Debt to Equity for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Due to net new long-term borrowings of 0.66%, Long Term Debt to Equity for Trailing Twelve Months Period improved to 0.04, a new company high.
Long Term Debt to Equity for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies in Major Pharmaceutical Preparations industry 31 other companies have achieved lower Long Term Debt to Equity for Trailing Twelve Months Period than Alx Oncology Holdings Inc. While total ranking remained unchanged compare to previous quarter at no. .

What is Long Term Debt to Equity Ratio?
What is ALXO selling?
Long Term Debt to Equity ALXO in the most recent quarter
Long Term Debt to Equity for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 32
Sector # 77
S&P 500 # 367


Long Term Debt to Equity for Trailing Twelve Months Period Statistics
High Average Low
0.04 0.02 0
(Sep 30 2023)   (Jun 30 2021)




Companies with similar average Long Term Debt to Equity for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Long Term Debt to Equity for Trailing Twelve Months Period
Advaxis Inc   0.11 
Immunogen inc   0.10 
Bicycle Therapeutics Plc  0.10 
Vaxxinity Inc   0.10 
Adial Pharmaceuticals Inc   0.09 
Imunon Inc   0.09 
Nabriva Therapeutics Plc  0.09 
Regeneron Pharmaceuticals Inc   0.09 
China Pharma Holdings Inc   0.08 
Rhythm Pharmaceuticals inc   0.08 
Ardelyx Inc   0.08 
Enlivex Therapeutics Ltd   0.07 
Prophase Labs Inc   0.07 
Compass Pathways Plc  0.07 
89bio Inc   0.07 
Equillium Inc   0.07 
Longeveron Inc   0.07 
Blue Water Biotech Inc   0.06 
Kineta Inc   0.06 
Celyad Oncology Sa  0.06 
Atai Life Sciences N v   0.06 
Aldeyra Therapeutics Inc   0.05 
Verona Pharma Plc  0.05 
Arcturus Therapeutics Holdings Inc   0.05 
Aptevo Therapeutics Inc   0.05 
Beigene ltd   0.05 
Hutchmed china Limited  0.05 
Frequency Therapeutics Inc   0.05 
Vaccinex Inc   0.05 
Nanoviricides inc   0.04 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com